STOCK TITAN

Evotec SE (EVO) Stock News, Nov 9, 2021

EVO NASDAQ

Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.

Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.

Rhea-AI Summary

Evotec SE has successfully closed a public offering of 20,000,000 American Depositary Shares (ADSs) on November 8, 2021, priced at $21.75 each, generating approximately $435 million in gross proceeds. An additional 3,000,000 ADSs may be purchased under an option, totaling expected proceeds of $500 million. The offering was managed by BofA Securities and Morgan Stanley, among others. Funds raised will support Evotec's innovative therapeutic projects across various therapeutic areas, enhancing its robust R&D pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags

FAQ

What is the current stock price of Evotec SE (EVO)?

Evotec SE (EVO) last closed at $1.45.

What is the market cap of Evotec SE (EVO)?

The market cap of Evotec SE (EVO) is approximately $515.3M.